212 related articles for article (PubMed ID: 36756390)
1. Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer.
Ding J; Sun Y; Sulaiman Z; Li C; Cheng Z; Liu S
Int J Gen Med; 2023; 16():367-391. PubMed ID: 36756390
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
Dai L; Guo X; Xing Z; Tao Y; Liang W; Shi Z; Hu W; Zhou S; Wang X
BMC Cancer; 2023 Jan; 23(1):102. PubMed ID: 36717836
[TBL] [Abstract][Full Text] [Related]
3. B7-H3/CD276: An Emerging Cancer Immunotherapy.
Zhou WT; Jin WL
Front Immunol; 2021; 12():701006. PubMed ID: 34349762
[TBL] [Abstract][Full Text] [Related]
4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
[TBL] [Abstract][Full Text] [Related]
7. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma.
Liang J; Liu Z; Pei T; Xiao Y; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Yin X; Chen N; Wei X; Lu Y; Zhu Y
Dis Markers; 2020; 2020():5354825. PubMed ID: 31998416
[TBL] [Abstract][Full Text] [Related]
9. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
10. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
[TBL] [Abstract][Full Text] [Related]
12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
13. Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification.
Sun K; Huang C; Li JZ; Luo ZX
World J Surg Oncol; 2022 Oct; 20(1):342. PubMed ID: 36253777
[TBL] [Abstract][Full Text] [Related]
14. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic and immunological values of RBM34 in osteosarcoma and its pan-cancer analysis.
Zhang W; He R; Cao W; Li D; Zheng Q; Zhang Y
Am J Cancer Res; 2023; 13(11):5094-5121. PubMed ID: 38058813
[TBL] [Abstract][Full Text] [Related]
16. B7-H3/CD276 and small-cell lung cancer: What's new?
Fabrizio FP; Muscarella LA; Rossi A
Transl Oncol; 2024 Jan; 39():101801. PubMed ID: 37865049
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
18. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
Huang S; Dong C; Li D; Xu Y; Wu J
Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
[No Abstract] [Full Text] [Related]
19. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
20. Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis.
Inamura K; Yokouchi Y; Kobayashi M; Sakakibara R; Ninomiya H; Subat S; Nagano H; Nomura K; Okumura S; Shibutani T; Ishikawa Y
Lung Cancer; 2017 Jan; 103():44-51. PubMed ID: 28024695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]